This review paper offers a thorough summary of how medication targeting is developing in the fields of nanomedicine and nanopharmacy. Drug delivery systems based on nanotechnology have become revolutionary instruments, providing therapeutic interventions with never-before-seen levels of accuracy and effectiveness. A range of techniques, from passive to active targeting mechanisms, are used in strategies for improved medication targeting. The utilization of passive targeting, which leverages the increased permeability and retention effect in tumors, has made it easier for nanoparticles to accumulate in certain disease areas. On the other hand, active targeting improves the precision of medication delivery by using ligands or biomolecules to guide nanoparticles to particular receptors. Prominent instances of efficacious implementations, such as liposomal doxorubicin formulations (Doxil®) and nanoparticle albumin-bound paclitaxel (Abraxane®), underscore the translational triumph of nanomedicine in clinical contexts, namely in the domain of oncology. But enduring difficulties, including manufacturing scalability, regulatory complexity, and biocompatibility, highlight the need for continued study and technical breakthroughs. Future prospects are also covered in the paper, with a focus on RNA-based treatments, smart drug delivery systems, personalized medicine, and artificial intelligence integration. Drug targeting in nanomedicine is positioned as a cornerstone in the future of therapeutic interventions, offering opportunities for more efficient, targeted, and customized treatments across a spectrum of diseases, thanks to the convergence of creative strategies, fruitful applications, and cutting-edge technologies.